Li PC, Yun DB, Huang YX, Huang QY. Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis. World J Clin Cases 2024; 12(25): 5739-5748 [DOI: 10.12998/wjcc.v12.i25.5739]
Corresponding Author of This Article
Qian-Yi Huang, MAMS, Master’s Student, Staff Physician, Department of Transfusion, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, No. 97 South Renmin Road, Shunqing District, Nanchong 637000, Sichuan Province, China. huangqianyi2019@163.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Peng-Cheng Li, De-Bo Yun, Department of Neurosurgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Ya-Xin Huang, Qian-Yi Huang, Department of Transfusion, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Author contributions: Li PC and Huang QY designed the research study; Li PC, Yun DB and Huang QY performed the research; Yun DB and Huang QY contributed analytic tools; Li PC, Huang QY and Huang YX analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors deny any conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian-Yi Huang, MAMS, Master’s Student, Staff Physician, Department of Transfusion, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, No. 97 South Renmin Road, Shunqing District, Nanchong 637000, Sichuan Province, China. huangqianyi2019@163.com
Received: February 22, 2024 Revised: May 27, 2024 Accepted: June 24, 2024 Published online: September 6, 2024 Processing time: 144 Days and 15.5 Hours
Abstract
BACKGROUND
Gliomas are the most common primary central nervous system neoplasm. Despite recent advances in the diagnosis and treatment of gliomas, patient prognosis remains dismal. Therefore, it is imperative to identify novel diagnostic biomarkers and therapeutic targets of glioma to effectively improve treatment outcomes.
AIM
To investigate the association between oligodendrocyte transcription factor 2 (Olig2) expression and the outcomes of glioma patients.
METHODS
The PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure databases were searched for studies (published up to October 2023) that investigated the relationship between Olig2 expression and prognosis of glioma patients. The quality of the studies was assessed using the Newcastle Ottawa Scale. Data analyses were performed using Stata Version 12.0 software.
RESULTS
A total of 1205 glioma patients from six studies were included in the meta-analysis. High Olig2 expression was associated with better outcomes in glioma patients [hazard ratio (HR): 0.81; 95% (confidence interval) CI: 0.51-1.27; P = 0.000]. Furthermore, the results of subgroup meta-analysis showed that high expression of Olig2 was associated with poor overall survival in European patients (HR: 1.34; 95%CI: 0.79-2.27) and better prognosis in Asian patients (HR: 0.43; 95%CI: 0.22-0.84). The sensitivity analysis showed that no single study had a significant effect on pooled HR, and there was also no indication of publication bias according to the Egger’s and Begger’s P value test or funnel plot test.
CONCLUSION
High Olig2 expression may have a positive impact on the prognosis of glioma patients, and should be investigated further as a prognostic biomarker and therapeutic target for glioma.
Core Tip: The overall prognostic value of oligodendrocyte transcription factor 2 (Olig2) for glioma remains unclear. We performed the first meta-analysis of previously published studies related to the potential prognostic value of Olig2 in glioma patients to evaluate the association between Olig2 expression and the outcomes of glioma patients. Our findings suggest that high Olig2 expression may have a positive impact on the prognosis of glioma patients, and should be investigated further as a prognostic biomarker and therapeutic target for glioma.
